| BID | 1.22 | ASK | 1.27 | ||
| Open | 1.21 | Previous Close | 1.26 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 2.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 96.85 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 41.62 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★ 39.26 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 34.55 | Earnings Rating | — | |
| Market Cap | 35.05M | Earnings Date | 21st Jul 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.25 | |
| Beta | -0.72 |
Today's Price Range 1.201.27 | 52W Range 0.61002.52 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -0.15% | ||
| 1 Month | 9.48% | ||
| 3 Months | 19.81% | ||
| 6 Months | 53.94% | ||
| 1 Year | 72.58% | ||
| 3 Years | -88.82% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -46.50 | |||
ROE last 12 Months | -129.06 | |||
ROA (5Y Avg) | -14.80 | |||
ROA last 12 Months | -47.75 | |||
ROC (5Y Avg) | -18.31 | |||
ROC last 12 Months | -67.23 | |||
Return on invested Capital Q | -12.97 | |||
Return on invested Capital Y | -22.15 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 0.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.40 | ||||
| 1.11 | ||||
| 1.11 | ||||
| 6.50 | ||||
| -1.50 | ||||
| -1.25 | ||||
| 1.11 | ||||
| 0.82 | ||||
| 33.41M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.10 | ||||
| 2.40 | ||||
| 0.64 | ||||
| 1.98 | ||||
| -10.90 | ||||
| Leverage Ratio | 3.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 15.80 | ||||
| -20.10 | ||||
| -9.40 | ||||
| -24.90 | ||||
| -79.14 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 22.41M | ||||
| 0.83 | ||||
| 64.15 | ||||
| 50.46 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2022 | - | -0.47 | - |
| Q01 2022 | - | -0.54 | - |
| Q04 2021 | - | -0.58 | - |
| Q03 2021 | -0.59 | -1.08 | -83.05 |
| Q02 2021 | -0.26 | -0.45 | -73.08 |
| Q01 2021 | -0.15 | -0.27 | -80.00 |
| Q04 2020 | - | 0.21 | - |
| Q03 2020 | -0.33 | -0.32 | 3.03 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 2.27K |
| Shares Outstanding | 27.60K |
| Shares Float | 8.72M |
| Trades Count | 24 |
| Dollar Volume | 2.80K |
| Avg. Volume | 17.80K |
| Avg. Weekly Volume | 16.35K |
| Avg. Monthly Volume | 12.41K |
| Avg. Quarterly Volume | 24.64K |
Centogene N.V. (NASDAQ: CNTG) stock closed at 1.27 per share at the end of the most recent trading day (a 0.79% change compared to the prior day closing price) with a volume of 2.27K shares and market capitalization of 35.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 442 people. Centogene N.V. CEO is Arndt Rolfs.
The one-year performance of Centogene N.V. stock is 72.58%, while year-to-date (YTD) performance is 36.56%. CNTG stock has a five-year performance of %. Its 52-week range is between 0.61 and 2.52, which gives CNTG stock a 52-week price range ratio of 34.55%
Centogene N.V. currently has a PE ratio of -0.40, a price-to-book (PB) ratio of 1.11, a price-to-sale (PS) ratio of 1.11, a price to cashflow ratio of 6.50, a PEG ratio of -, a ROA of -47.75%, a ROC of -67.23% and a ROE of -129.06%. The company’s profit margin is -79.14%, its EBITDA margin is -9.40%, and its revenue ttm is $22.41 Million , which makes it $0.83 revenue per share.
Of the last four earnings reports from Centogene N.V., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Centogene N.V.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Centogene N.V. is Strong Buy (1), with a target price of $2.5, which is +96.85% compared to the current price. The earnings rating for Centogene N.V. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Centogene N.V. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Centogene N.V. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.99, ATR14 : 0.09, CCI20 : 43.94, Chaikin Money Flow : 0.39, MACD : 0.03, Money Flow Index : 44.84, ROC : 1.20, RSI : 53.85, STOCH (14,3) : 69.09, STOCH RSI : 0.29, UO : 64.85, Williams %R : -30.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Centogene N.V. in the last 12-months were:
Centogene N.V.
Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It's pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.
CEO: Arndt Rolfs
Telephone: +49 38180113400
Address: Am Strande 7, Rostock 18055, , DE
Number of employees: 442
